Document Detail


Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis.
MedLine Citation:
PMID:  3282846     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy and safety of omeprazole, 40 mg once daily for four to eight weeks of treatment, were studied in 61 patients with ulcerative reflux esophagitis. A double-blind controlled study design was used, and the patients were randomly allocated to treatment with either omeprazole 40 mg once daily or ranitidine 150 mg twice daily. Endoscopy was performed prior to inclusion into the study, after four weeks and, if unhealed, again after eight weeks. Healing of esophagitis was defined as complete disappearance of all esophageal ulcerations. Symptoms were recorded before entry, after four weeks, and again after eight weeks in unhealed patients. Fifty-one patients were included in the per-protocol analysis at day 29, and 50 patients at day 57. The healing rate after four weeks of treatment was 22 of 26 patients (85%) treated with omeprazole and 10 of 25 patients (40%) treated with ranitidine (P less than 0.001). The corresponding figures after eight weeks were 24 of 25 (96%), and 13 of 25 (52%) (P less than 0.001). These results were confirmed in the intent-to-treat analysis. Patients treated with omeprazole showed a significantly faster and more profound relief in heartburn than patients treated with ranitidine: 85% had no heartburn after four weeks of treatment with omeprazole compared to 24% in patients treated with ranitidine (P = 0.00007). The percentage of patients who were free of all reflux symptoms was significantly greater in the omeprazole-treated group as compared to the ranitidine-treated group (62% and 12% respectively; P = 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
G Vantrappen; L Rutgeerts; P Schurmans; J L Coenegrachts
Related Documents :
11167966 - Topical sucralfate in the management of peristomal skin disease: an open study.
329786 - Phenothiazine-induced ecg abnormalities: effect of a glucose load.
6119776 - Ranitidine: a pilot study in japan.
6377466 - Relapse prevention of duodenal ulcers with trimipramine, cimetidine, or placebo. a doub...
23971656 - Quality of life assessment by applying eortc questionnaires to rectal cancer patients a...
6375596 - Aortic and mitral valve replacement with the st. jude medical prosthesis.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  33     ISSN:  0163-2116     ISO Abbreviation:  Dig. Dis. Sci.     Publication Date:  1988 May 
Date Detail:
Created Date:  1988-06-02     Completed Date:  1988-06-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  523-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Clinical Trials as Topic
Double-Blind Method
Drug Administration Schedule
Esophagitis, Peptic / drug therapy*
Female
Humans
Male
Middle Aged
Omeprazole / therapeutic use*
Random Allocation
Ranitidine / therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
66357-35-5/Ranitidine; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adenosquamous-cell carcinoma in ulcerative colitis. Report of a case.
Next Document:  Effect of nifedipine on gastric emptying and gastrointestinal motility in man.